Anebulo Pharmaceuticals (NASDAQ:ANEB) Announces Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Trading Down 2.6 %

ANEB stock traded down $0.05 during trading on Friday, reaching $1.91. The stock had a trading volume of 3,269 shares, compared to its average volume of 6,842. The firm has a fifty day moving average price of $2.05 and a 200 day moving average price of $2.35. The company has a market capitalization of $49.53 million, a P/E ratio of -5.30 and a beta of -1.01. Anebulo Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $3.61.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.